Literature DB >> 11836409

Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection.

J Norman Flynn1, Stephen P Dunham, Vivien Watson, Oswald Jarrett.   

Abstract

Feline leukemia virus (FeLV) is a common naturally occurring gammaretrovirus of domestic cats that is associated with degenerative diseases of the hematopoietic system, immunodeficiency, and neoplasia. Although the majority of cats exposed to FeLV develop a transient infection and recover, a proportion of cats become persistently viremic and many subsequently develop fatal diseases. To define the dominant host immune effector mechanisms responsible for the outcome of infection, we studied the longitudinal changes in FeLV-specific cytotoxic T lymphocytes (CTLs) in a group of naïve cats following oronasal exposure to FeLV. Using (51)Cr release assays to measure ex vivo virus-specific cytotoxicity, the emerging virus-specific CTL response was correlated with modulations in viral burden as assessed by detection of infectious virus, FeLV p27 capsid antigen, and proviral DNA in the blood. High levels of circulating FeLV-specific effector CTLs appeared before virus neutralizing antibodies in cats that recovered from exposure to FeLV. In contrast, persistent viremia was associated with a silencing of virus-specific humoral and cell-mediated host immune effector mechanisms. A single transfer of between 2 x 10(7) and 1 x 10(8) autologous, antigen-activated lymphoblasts was associated with a downmodulation in viral burden in vivo. The results suggest an important role for FeLV-specific CTLs in retroviral immunity and demonstrate the potential to modulate disease outcome by the adoptive transfer of antigen-specific T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836409      PMCID: PMC135947          DOI: 10.1128/jvi.76.5.2306-2315.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Comparison of diagnostic methods for feline leukemia virus and feline immunodeficiency virus.

Authors:  O Jarrett; A M Pacitti; M J Hosie; G Reid
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

2.  Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses.

Authors:  M A Stewart; M Warnock; A Wheeler; N Wilkie; J I Mullins; D E Onions; J C Neil
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

4.  Humoral immune reactivity to feline leukemia virus and associated antigens in cats naturally infected with feline leukemia virus.

Authors:  H Lutz; N Pedersen; J Higgins; U Hübscher; F A Troy; G H Theilen
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

Review 5.  Feline leukaemia viruses: molecular biology and pathogenesis.

Authors:  J C Neil; D E Onions
Journal:  Anticancer Res       Date:  1985 Jan-Feb       Impact factor: 2.480

6.  Detection of transient and persistent feline leukaemia virus infections.

Authors:  O Jarrett; M C Golder; M F Stewart
Journal:  Vet Rec       Date:  1982-03-06       Impact factor: 2.695

7.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

9.  Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity.

Authors:  L K Borysiewicz; S Morris; J D Page; J G Sissons
Journal:  Eur J Immunol       Date:  1983-10       Impact factor: 5.532

10.  Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27.

Authors:  H Lutz; N C Pedersen; R Durbin; G H Theilen
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

View more
  19 in total

1.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

2.  Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma.

Authors:  A Katrin Helfer-Hungerbuehler; Valentino Cattori; Felicitas S Boretti; Pete Ossent; Paula Grest; Manfred Reinacher; Manfred Henrich; Eva Bauer; Kim Bauer-Pham; Eva Niederer; Edgar Holznagel; Hans Lutz; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2010-02-19       Impact factor: 4.602

3.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

4.  Polymorphisms and tissue expression of the feline leukocyte antigen class I loci FLAI-E, FLAI-H, and FLAI-K.

Authors:  Jennifer C Holmes; Savannah G Holmer; Peter Ross; Adam S Buntzman; Jeffrey A Frelinger; Paul R Hess
Journal:  Immunogenetics       Date:  2013-06-30       Impact factor: 2.846

5.  Development and application of a quantitative real-time PCR assay to detect feline leukemia virus RNA.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

6.  Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.

Authors:  M Patel; K Carritt; J Lane; H Jayappa; M Stahl; M Bourgeois
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

7.  Retroviral DNA--the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats.

Authors:  Stefanie Nesina; A Katrin Helfer-Hungerbuehler; Barbara Riond; Felicitas S Boretti; Barbara Willi; Marina L Meli; Paula Grest; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2015-12-21       Impact factor: 4.602

8.  Antibody response against koala retrovirus (KoRV) in koalas harboring KoRV-A in the presence or absence of KoRV-B.

Authors:  O Olagoke; B L Quigley; M V Eiden; P Timms
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

9.  Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection.

Authors:  Andrea Major; Valentino Cattori; Eva Boenzli; Barbara Riond; Peter Ossent; Marina Luisa Meli; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2009-10-28       Impact factor: 3.683

Review 10.  Clinical aspects of feline retroviruses: a review.

Authors:  Katrin Hartmann
Journal:  Viruses       Date:  2012-10-31       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.